← Back to Search

Diabetes Education + Food Assistance for Type 2 Diabetes (LIFT-DM Trial)

N/A
Waitlist Available
Led By Leonard E Egede, MD
Research Sponsored by Medical College of Wisconsin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12-months post randomization
Awards & highlights

LIFT-DM Trial Summary

This trial is testing whether monthly food vouchers or monthly mailed food boxes are better for glycemic control in low income, food insecure, African Americans with Type 2 Diabetes. The trial will also test whether providing diabetes education in combination with food supplementation leads to improved clinical outcomes compared to education alone.

Who is the study for?
This trial is for African American adults with Type 2 Diabetes who are experiencing food insecurity, have an income at or below 133% of the federal poverty level or are Medicaid eligible, and can communicate in English. Participants must be over 21 years old with a clinical diagnosis of diabetes and HbA1c levels >=8%. Those with drug/alcohol dependency, short life expectancy, significant dementia, active psychosis, or involvement in other diabetes trials cannot join.Check my eligibility
What is being tested?
The LIFT-DM study is testing whether monthly mailed stock boxes of food or monthly food vouchers improve blood sugar control better than just diabetes education alone. It's also checking if combining both stock boxes and vouchers has a superior effect. Participants will be randomly assigned to one of four groups: only education; education plus stock boxes; education plus vouchers; or all three combined.See study design
What are the potential side effects?
Since this trial involves non-medical interventions like food assistance and educational support rather than drugs or medical procedures, there aren't typical side effects as seen in pharmaceutical trials. However, participants may experience changes in diet habits.

LIFT-DM Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12-months post randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12-months post randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Glycemic control (HbA1c)
Secondary outcome measures
Blood Pressure
LDL-Cholesterol
Quality of Life as measured by the SF-12

LIFT-DM Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Group 4 -- Diabetes Education Plus Combination of Monthly FoodExperimental Treatment1 Intervention
Individuals assigned to this group will receive diabetes education and skills training, monthly food vouchers for use at local Farmer's markets mailed to their home, and monthly stock boxes with diabetes appropriate food items mailed to their home.
Group II: Group 3 - Diabetes Education Plus Monthly Stock BoxesExperimental Treatment1 Intervention
Individuals assigned to this group will receive diabetes education and skills training and monthly stock boxes with diabetes appropriate food items mailed to their home.
Group III: Group 2 - Diabetes Education Plus Monthly Food VouchersExperimental Treatment1 Intervention
Individuals assigned to this group will receive diabetes education and skills training and monthly food vouchers for use at local Farmer's markets mailed to their home.
Group IV: Group 1- Diabetes Education OnlyActive Control1 Intervention
Individuals assigned to this group will receive diabetes education and skills training but will not receive food supplementation.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Type 2 Diabetes include lifestyle modifications, oral hypoglycemic agents, and insulin therapy. Lifestyle modifications, such as diet and exercise, improve insulin sensitivity and promote weight loss, which is crucial for glycemic control. Oral hypoglycemic agents like metformin reduce hepatic glucose production and increase insulin sensitivity, while sulfonylureas stimulate insulin secretion from pancreatic beta cells. Insulin therapy directly supplements insulin levels to manage blood glucose. Nutritional support, as studied in the trial with mailed stock boxes and food vouchers, is essential because it ensures consistent access to healthy foods, aiding in weight management and glycemic control, which are foundational to managing Type 2 Diabetes.
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.Assessing the impact of a new delivery method of insulin on glycemic control using a novel trial design.Overcoming obstacles in risk factor management in type 2 diabetes mellitus.

Find a Location

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor
610 Previous Clinical Trials
1,162,231 Total Patients Enrolled
Leonard E Egede, MDPrincipal InvestigatorMedical College of Wisconsin
Rebekah J Walker, PhDPrincipal InvestigatorMedical College of Wisconsin
1 Previous Clinical Trials
150 Total Patients Enrolled

Media Library

Diabetes Education Plus Combination of Monthly Food Vouchers and Stock Boxes Clinical Trial Eligibility Overview. Trial Name: NCT04181424 — N/A
Type 2 Diabetes Research Study Groups: Group 1- Diabetes Education Only, Group 3 - Diabetes Education Plus Monthly Stock Boxes, Group 2 - Diabetes Education Plus Monthly Food Vouchers, Group 4 -- Diabetes Education Plus Combination of Monthly Food
Type 2 Diabetes Clinical Trial 2023: Diabetes Education Plus Combination of Monthly Food Vouchers and Stock Boxes Highlights & Side Effects. Trial Name: NCT04181424 — N/A
Diabetes Education Plus Combination of Monthly Food Vouchers and Stock Boxes 2023 Treatment Timeline for Medical Study. Trial Name: NCT04181424 — N/A
~55 spots leftby Jun 2025